Table 3 Treatments and outcomes according to different thyroid function categories among patients with COVID-19
| Â | NTF | Subclinical hypothyroidism | Severe NTIS | Mild to moderate NTIS | P values |
|---|---|---|---|---|---|
No. of participants | 184 | 17 | 11 | 23 | Â |
Treatments, % | |||||
 Antiviral therapy | 162 (88.0) | 15 (88.2) | 8 (72.7) | 20 (87.0) | 0.455 |
 Antibiotic therapy | 104 (56.5) | 8 (47.1) | 9 (81.8) | 20 (87.0) | 0.010 |
 Use of corticosteroid | 37 (20.1) | 4 (23.5) | 6 (54.5) | 12 (52.2) | 0.001 |
 Intravenous immunoglobin | 18 (9.8) | 3 (17.6) | 5 (45.5) | 11 (47.8) | < 0.001 |
 Antihypertensive medicine | 56 (30.4) | 10 (58.8) | 4 (36.4) | 9 (39.1) | 0.110 |
 Glucose-lowering medicine | 35 (19.0) | 1 (5.9) | 2 (18.2) | 6 (26.1) | 0.451 |
 Lipid-lowering medicine | 16 (8.7) | 0 (0.0) | 1 (9.1) | 2 (8.7) | 0.686 |
Illness severity, % | 0.005 | ||||
 Non-severe | 45 (24.5) | 4 (23.5) | 0 (0.0) | 0 (0.0) | 0.005 |
 Severe | 139 (75.5) | 13 (76.5) | 11 (100.0) | 23 (100.0) | 0.005 |
Complications, % | |||||
 ARDS | 2 (1.1) | 0 (0.0) | 1 (9.1) | 3 (13.0) | 0.009 |
 Acute cardiac injury | 27 (15.3) | 4 (23.5) | 7 (70.0) | 12 (54.5) | < 0.001 |
 Acute kidney injury | 5 (2.7) | 0 (0.0) | 3 (27.3) | 5 (21.7) | < 0.001 |
 Shock | 3 (1.6) | 0 (0.0) | 4 (36.4) | 11 (47.8) | < 0.001 |
 Hypoalbuminemia (albumin < 30 g/L) | 34 (18.6) | 4 (23.5) | 5 (45.5) | 12 (52.2) | 0.001 |
 Coagulopathy | 19 (10.9) | 0 (0.0) | 3 (27.3) | 6 (30.0) | 0.015 |
 Length of hospital stay, days | 23.4 (0.99) | 25.5 (3.23) | 24.8 (4.02) | 23.1 (2.89) | 0.917 |